Search Results - cell+therapy

64 Results Sort By:
Orthogonal Cytokine Enhanced CAR T Cells Generated Through Gene Editing
Brief Description: The present disclosure provides methods of producing a modified immune cell responsive to orthogonal cytokine signaling and a modified immune cell produced by said method. The present disclosure further provides a modified immune cell responsive to orthogonal cytokine signaling and methods for treating cancer comprising the modified...
Published: 8/21/2025   |   Inventor(s): K. Christopher Garcia, Michael Milone, Qian Zhang
Keywords(s): Cell Therapy, Immunology, Immunoncology, Immunotherapy, Oncology, Platform Technology
Category(s): Technology Classifications > Therapeutics
Methods and Compositions for Predicting Cancer Survival and Car T Cell Toxicity
Brief Description: The present disclosure relates to compositions and methods for predicting cancer survival or toxicity in a subject receiving a chimeric antigen receptor (CAR) T cell therapy. The present disclosure further discloses compositions, e.g., pharmaceutical compositions, and methods for treating said subject. Image: Caption: Reference...
Published: 8/19/2025   |   Inventor(s): Marco Ruella, Andrea Facciabene
Keywords(s): Cell Therapy, Oncology
Category(s): Technology Classifications > Therapeutics
Engineered Chimeric Antigen Receptor (CAR) Microglia-Like Cells for the Treatment of Neurodegenerative Disorders
Brief Description: Engineered stem cell/monocyte/macrophage/glia for the treatment and prevention of neurodegenerative disorders associated with misfolded proteins or glia dyshomeostasis. The present disclosure provides compositions and methods comprising chimeric antigen receptors (CARs) specific for amyloid beta (Aβ) and/or Tau. In certain...
Published: 8/19/2025   |   Inventor(s): Matias Porras Paniagua, Saar Gill, Frederick Christian Bennett
Keywords(s): Cell Therapy, Immunotherapy, Neurodegenerative Diseases
Category(s): Technology Classifications > Therapeutics
Compositions and methods of chimeric autoantibody receptor T cells expressing extended phospholipase A2 receptor fragments
Brief Description: The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an anti-phospholipase A2 receptor (PLA2R) autoantibody-based B cell receptor (BCR), polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant cells (e.g., T cells) comprising...
Published: 8/19/2025   |   Inventor(s): Aimee Payne, Baomei Wang
Keywords(s): Cell Therapy, Immunotherapy, Nephrology and Urology
Category(s): Technology Classifications > Therapeutics
Controllable stimulation of genetically engineered lymphocytes for the treatment of cancer
Brief Description: The present disclosure provides methods for controllable stimulation of genetically engineered lymphocytes. Compositions and methods of treatment are also provided. Image: Caption: Reference Media Title: Reference Media: Intellectual Property Title: Intellectual Property: Intellectual Property: US 2025/0057883 A1 Docket Number:...
Published: 8/19/2025   |   Inventor(s): Saar Gill
Keywords(s): Cell Therapy, Immunotherapy, Oncology
Category(s): Technology Classifications > Therapeutics
Peptides For Solid Cancer Tumor Immunotherapy Treatment
Short, multivalent peptide antagonists to block macrophage immune-receptor SIRPα, promoting cancer cell phagocytosis. Problem: Modern cancer cell immunotherapies incorporate immune checkpoint blockade mechanisms, where prominent therapies target functionally suppressed immune cells in tumor microenvironments. Relieving this suppression allows...
Published: 8/11/2025   |   Inventor(s): Dennis Discher, AbdelAziz Jalil
Keywords(s): Cell Therapy, Immunology, Oncology
Category(s): Technology Classifications > Chemical Processes and Synthesis, Technology Classifications > Therapeutics, Technology Classifications > Vaccines
Anticancer IgG Against Multiple Epitopes on Live Tumors Upon Disruption of ‘Self’ Signaling by CD47
A method to combine two or three monoclonal antibodies (mABs) into one treatment to successfully bind to multiple cancer cell surface epitopes and promote targeted degradation by phagocytosis. Problem: Phagocytosis of ‘self’ cells is generally inhibited by a key macrophage checkpoint interaction between SIRPα on the macrophage and...
Published: 2/27/2025   |   Inventor(s): Dennis Discher, Jason Andrechak, Lawrence Dooling
Keywords(s): Antibody, Bioengineering, Cell Therapy, Drug Target, Immunology, Immunoncology, Immunotherapy, Oncology, Platform Technology
Category(s): Technology Classifications > Therapeutics
T-Cell-Activating Lipid Nanoparticles for Rapid Engineering of CAR T Cells
A method to streamline the process of generating chimeric antigen receptor (CAR) T cells for therapeutic applications. Problem: CAR T cell therapy has demonstrated clinical success in treating various forms of cancer. With more CAR T cell therapies projected to gain regulatory approval, manufacturing becomes increasingly important in the face of this...
Published: 12/20/2024   |   Inventor(s): Ann Metzloff, Margaret Billingsley, Michael Mitchell
Keywords(s): Bioengineering, Cell Therapy, Drug Delivery, Immunoncology, Immunotherapy, Oncology, Platform Technology
Category(s): Technology Classifications > Therapeutics
Method to Alleviate Side Effects of CAR T Cell Immunotherapies
CAR-T cells are PEGylated to block the interactions with monocytes and macrophages to reduce the side effects of CAR-T cell therapies (cytokine release syndrome and neurotoxicity). Problem: CAR-T cell therapies lead to many adverse side effects such as cytokine release syndrome (CRS) and neurotoxicity. It has been shown that 20-70% of patients receiving...
Published: 12/20/2024   |   Inventor(s): Michael Mitchell, Ningqiang Gong
Keywords(s): Bioengineering, Cell Therapy, Immunology, Immunoncology, Immunotherapy, Oncology
Category(s): Technology Classifications > Chemical Processes and Synthesis, Technology Classifications > Therapeutics
Safe and Potent mRNA Lipid Nanoparticles (LNPs) for Ex-Vivo Engineering of Immunosuppressive T cells in Autoimmunity Therapies.
Using mRNA-LNPs to deliver forkhead box protein 3 (Foxp3) to CD4+ T cells to engineer Foxp3-positive T (FP3T) cells with immunosuppressive properties. Problem: Autoimmune disorders (e.g., type 1 diabetes, multiple sclerosis, and myasthenia gravis) are mediated by self-reactive lymphocyte (B or T cells) expansion. Available suppressive medications like...
Published: 10/1/2024   |   Inventor(s): Michael Mitchell, Ajay Thatte, Alvin Mukalel
Keywords(s): Bioengineering, Cell Therapy, Drug Delivery, Immunology, Immunotherapy, Platform Technology
Category(s): Technology Classifications > Chemical Processes and Synthesis, Technology Classifications > Therapeutics
1 2 3 4 5 6 7